Cardiovascular toxicity in breast cancer patients – contributors and role of cardioprotective drugs

Submitted: December 30, 2022
Accepted: January 30, 2023
Published: March 28, 2023
Accepted: January 30, 2023
Abstract Views: 1317
PDF: 321
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Lorenzo Carriera, Sara Caporuscio, Marta Fantò, Alice D’Abramo, Genesio Puzio, Luca Triolo, Angelo Coppola, Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review , Monaldi Archives for Chest Disease: Early Access
- Marzia Testa, Eleonora Indolfi, Guido Pastorini, Enrica Conte, Mauro Feola, The gatekeeper images in hypertrophic cardiomyopathy: the role of native T1 mapping in Anderson-Fabry disease , Monaldi Archives for Chest Disease: Early Access
You may also start an advanced similarity search for this article.